This article is more than 5 years old. Information may no longer be current.
Pfizer, Eli Lilly and Company announce positive outcomes with OA treatment
Click Here to Manage Email Alerts
Pfizer Inc. and Eli Lilly and Company announced that a 16-week phase 3 study showed patients with osteoarthritis who received two doses of tanezumab, an investigational humanized monoclonal antibody, separated by 8 weeks had a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA.
“There is a substantial need for innovative new treatment options for osteoarthritis, as many patients are unable to find relief with currently available medicines and continue to suffer,” Ken Verburg, tanezumab development team leader at Pfizer Global Produce Development, said in a company press release. “We are encouraged by these results, which speak to the potential of tanezumab as a non-opioid treatment option for pain reduction and improvement in physical function in people living with osteoarthritis pain.”
The release noted that tanezumab was generally well tolerated, with approximately 1% of patients who discontinued tanezumab treatment due to adverse events, and patients treated with tanezumab had rapidly progressive OA at a frequency of less than 1.5% vs. placebo.
The FDA granted fast track designation for tanezumab for the treatment of OA pain and chronic low back pain in June 2017, according to the release, the first nerve growth factor inhibitor to receive this designation.
“We look forward to continuing to advance tanezumab in our ongoing global phase 3 development program, which includes six studies in approximately 7,000 patients with osteoarthritis, chronic low back pain and cancer pain,” Christi Shaw, senior vice president of Eli Lilly and Company and president of Lilly Bio-Medicines, said in the release.
Reference: